NCT04642937View on ClinicalTrials.gov

Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma

PHASE1UnknownINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2024

Conditions

Glioblastoma

Interventions

DRUG

Treatment with hP1A8

Treatment with hP1A8

Trial Locations (1)

55455

University of Minnesota, Minneapolis

Sponsors

Lead Sponsor

OX2 Therapeutics

All Listed Sponsors

lead

OX2 Therapeutics

INDUSTRY